Liver cancer.

Area of Science:

• Hepatology
• Oncology
• Public Health

Background:

• Hepatocellular carcinoma (HCC) presents a dismal prognosis, with 5-year survival rates below 25% even for surgically resectable cases and median survival under 1 year for advanced disease.
• Despite poor prognosis, HCC is a preventable malignancy, offering hope for improved patient outcomes.

Purpose of the Study:

• To highlight the preventable nature of Hepatocellular carcinoma (HCC).
• To review successful public health interventions and ongoing research for HCC prevention.

Main Methods:

• Analysis of HCC incidence rates in Taiwanese children before and after the implementation of a neonatal vaccination program.
• Review of existing literature on antiviral therapies (e.g., Interferon) for viral hepatitis in relation to HCC development.
• Examination of investigational agents (e.g., polyprenoic acid, acyclic retinoid) for preventing secondary primary tumors post-HCC resection.

Main Results:

• A significant decrease in childhood HCC rates (from 5.2 to 1.3 per million) was observed in Taiwan following the 1984 neonatal vaccination program.
• Interferon treatment for viral hepatitis shows potential in reducing long-term HCC incidence.
• Research is ongoing into agents like polyprenoic acid and acyclic retinoid for preventing recurrence after HCC resection.

Conclusions:

• Hepatocellular carcinoma (HCC) is a preventable disease, with vaccination programs demonstrating substantial public health impact.
• Antiviral therapies and novel chemopreventive agents represent key strategies in the ongoing fight against HCC.